Team SunilMadhavs World

Discontinuing SSRIs or SNRIs during pregnancy was associated with nearly double the risk of mental health emergencies, according to a cross-sectional analysis of 3,983 women. While prepregnancy psychiatric visit rates were similar between groups, antidepressant discontinuation was linked to significantly higher emergency department visits for psychiatric indications, particularly during the first and ninth months of pregnancy. These findings highlight the maternal risks of routine antidepressant discontinuation and reinforce the importance of individualized risk–benefit counseling during pregnancy.

A large UK Biobank analysis found that higher serum vitamin D levels were associated with a lower risk of hospitalization for respiratory tract infections, while severe deficiency increased risk. Although causality remains unproven, the findings position vitamin D status as a potentially modifiable factor in preventive health strategies.

Statin Therapy and Risk of Acute Exacerbations in Adults With Mild Asthma Background     Statins, widely prescribed for cardiovascular disease prevention, exhibit pleiotropic effects that extend beyond lipid lowering. …

FDA Restrictions on Non-Approved GLP-1 API Use and Marketing   The US Food and Drug Administration (FDA) has announced plans to implement restrictions on the use of glucagon-like peptide-1 (GLP-1) …

Association Between Target Urate Levels and Cardiovascular Outcomes in Gout   Data published in JAMA Internal Medicine indicates that patients with gout who successfully achieve a serum urate level of …

  A novel cellular rejuvenation therapy, ER-100, has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with human clinical testing, marking what the sponsor describes as …

Patients undergoing maintenance hemodialysis continue to experience disproportionately high mortality and substantial treatment-related burden. Among the modifiable aspects of dialysis care, treatment duration represents a potentially powerful yet underused lever …

Brief Report: Prevalence and Economic Burden of Chronic Conditions in the Commercially Insured US Population (2024) Overview A 2024 analysis conducted by FAIR Health presents new data regarding the epidemiology …

  Key takeaways: Using NHANES data from 2017 to 2023, obesity prevalence in the U.S. is 75.2% when excess adiposity cutoffs are used. Among adults with a BMI of less …

Excerpt:
The FDA has granted approval to Novartis for Itvisma (onasemnogene abeparvovec-brve), the first gene replacement therapy for spinal muscular atrophy (SMA) available for patients aged 2 years and older. Backed by data from the Phase 3 STEER and Phase 3b STRENGTH trials, this one-time intrathecal treatment addresses the genetic root cause of SMA and is expected to be available in the U.S. this December.